Circe Biomedical is developing innovative cell technologies and systems for diseases of the liver and pancreas.

Circe Biomedical is a privately held biomedical company engaged in the development, production, and commercialization of bioartificial organs and therapeutic cell systems. Circe's systems are intended to replace the function of a failing organ by integrating living cells with extracorporeal and implantable devices.

The company's lead product in development, the HepatAssist® Liver Support System integrates viable liver cells with biocompatible membranes into an extracorporeal, bioartificial liver assist system.  The HepatAssist System is designed to bridge patients with acute liver failure to organ recovery or transplantation. This system has progressed further in controlled clinical trials for acute liver failure than any other system being evaluated today.

The PancreAssist® System, which is in pre-clinical development, is an implantable, bioartificial pancreas incorporating living pancreatic islets, and is designed as a novel therapy for the treatment of insulin-dependent diabetes.